Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 28, 2022Frontiers in OncologyOpen Access

Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma

View Full Paper
Ask AI
Bookmark
Share

Key result

High-risk 10-cuproptosis-related lncRNA signature linked to shorter overall survival in colon adenocarcinoma.

  • P<0.001
  • n=446

Why the study?

The role and prognostic value of cuproptosis-related lncRNAs in colon adenocarcinoma remained unknown.

Population

COAD patients with expression profiles and clinical data from TCGA

Comparison

High-risk vs low-risk groups defined by a 10 cuproptosis-related-lncRNA prognostic signature

Design

Bioinformatics and in vitro validation study

Authors

MXMiaorong XuChinese University of Hong KongJMJiayi MuZhejiang UniversityJWJiaojiao WangHangzhou Normal University

Discussion

Loading...

Member takes

Implication

Requires prospective validation before clinical use in colon adenocarcinoma; extends cuproptosis-lncRNA research but remains hypothesis-generating.

Study Design

Type

Observational (n=446)

Structured PICO

P
Population
446 patients with colon adenocarcinoma from the TCGA database, divided into training and validation cohorts to evaluate a cuproptosis-related lncRNA prognostic signature.
E
Exposure
10 cuproptosis-related-lncRNA prognostic signature (high-risk group)
C
Comparator
Low-risk group based on the 10 cuproptosis-related-lncRNA prognostic signature
O
Outcome
Overall survival (OS) timehard clinical

Main Result

p-value: p=<0.001

A 10-cuproptosis-related lncRNA signature can independently predict overall survival and drug sensitivity in colon adenocarcinoma patients.

Limitations

  • The risk signature was created using public data and lacks novel clinical samples and data.
  • The model had to be validated in one database because no other databases have available lncRNA expression and clinical data.
  • qRT-PCR was only performed on 11 pairs of clinical samples to verify the expression of ten cuproptosis-related lncRNAs due to insufficient samples.

Cite This Study

Xu et al. (2022) conducted an observational in Colon adenocarcinoma (n=446). High-risk score based on a 10-cuproptosis-related lncRNA signature vs. Low-risk score was evaluated on Overall survival (p=<0.001). A high-risk score derived from a 10-cuproptosis-related lncRNA signature was an independent risk factor for shorter overall survival in patients with colon adenocarcinoma (p<0.001, 3-year AUC 0.879).

synapsesocial.com/papers/6aa9ed44663efc0f70843f18https://doi.org/10.3389/fonc.2022.961213
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors2009 · 2,048 citations
  2. 2Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries2021 · 114,850 citations
  3. 3Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates2010 · 2,975 citations
  4. 4Functional annotation of human long noncoding RNAs via molecular phenotyping2020 · 199 citations
  5. 5Global trends in colorectal cancer mortality: projections to the year 20352018 · 578 citations